DS
THRX

David Shaw’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

David Shaw’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,412
Closed -$58K – 5649
2022
Q2 		$58K Buy
+10,412
New +$86K ﹤0.01% 4821
2022
Q1 		– Sell
-22,136
Closed -$281K – 6085
2021
Q4 		$281K Buy
+22,136
New +$334K ﹤0.01% 4715

Other funds holding THRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

David Shaw's THRX Position: Q3 2022 in Review

David Shaw sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q3 2022, closing a stake of 10,412 shares — an estimated $58K sold.

David Shaw first reported a position in THRX in Q4 2021 and held it in 2 quarters. The position peaked at $281K in Q4 2021. 51 funds tracked by Wall St. Rank hold THRX as of Q3 2022.

  • David Shaw reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 10,412 Theseus Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $58K.
  • David Shaw first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • David Shaw's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $281K in Q4 2021.
  • 51 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.